Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148395
Status:
COMPLETED
Last Update Posted:
2008-04-22
First Post:
2005-09-07
Brief Title:
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer Sequential Single-Agent vs Double-Agent vs Triple-Agent Therapy
Sponsor:
Aktion Bronchialkarzinom eV
Organization:
Aktion Bronchialkarzinom eV
Study Overview
Official Title:
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer Sequential Single-Agent vs Double-Agent vs Triple-Agent Therapy
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer
It claims less on the efficacy of different chemotherapy combinations than more on the comparison of different strategies of sequential single-agent sequential double-agent or sequential triple-agent therapy
It claims less on the efficacy of different chemotherapy combinations than more on the comparison of different strategies of sequential single-agent sequential double-agent or sequential triple-agent therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None